- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
This Article
Services
Google Scholar
PubMed
Acta Endocrinologica (Buc)
Matei VP, Mihailescu A, Paraschiv G, Al-Bataineh R, Purnichi T
Weight Gain and Antipsychotics. Data from EUFEST Study
Acta Endo (Buc) 2016, 12 (2): 177-184doi: 10.4183/aeb.2016.177
Context. Schizophrenia is a chronic disease most
frequently necessitating lifelong antipsychotic treatment.
Selecting which antipsychotic is to be prescribed in an
individual schizophrenia patient represents an important
clinical decision that need to take into account efficacy and
side effects.
Objective. Evaluating weight gain related with
one year antipsychotic treatment in antipsychotic naive firstepisode
schizophrenia patients.
Design. This study is an analysis of weight gain
associated with typical or atypical antipsychotics used in
European First Episode Schizophrenia Trial (EUFEST) study.
Subjects and Methods. 113 first episode naïve
antipsychotic schizophrenia patients included in EUFEST
- Romanian cohort, who were randomized to one of the 5
treatment arms. Weight was obtained at baseline, 3, 6, 9 and
12 months for the 5 antipsychotics (typical-Haloperidol;
atypical-Olanzapine, Amisulpride, Ziprasidone, Quetiapine).
Results. There are no statistically significant
differences between groups treated with typical or atypical
antipsychotics or between any individual antipsychotics
concerning weight gain during the study. Weight gain was
the highest in the first 3 months (57.49%) for all the studied
neuroleptics. At the end of the study, the less increase was
observed with ziprasidone (3.87 kg) and the highest with
olanzapine (9.83 kg).
Conclusion. Increase in weight has taken place
for each individual neuroleptic, but also as a group (all
neuroleptics) in the first three months (57.49%). Therefore,
we should address the issue of weight gain with great care,
especially in first period of antipsychotic administration,
in order to fast deploy intervention tailored to maintain pretreatment
weight.
Keywords: antipsychotics, schizophrenia, weight gain.
Correspondence: Valentin Petre Matei MD, “Prof. Dr. Alexandru Obregia” Clinical Psychiatric Hospital, Psychiatry Department, 2nd Department, Berceni Street, no.10, District 4, Bucharest, 041914, Romania, E-mail: valipmatei@yahoo.com